After 1:10 Stock Split, Multibagger Pharma Stock Announces Strategic Acquisitions; 300% Return 1 Yr

Sudarshan Pharma Industries Limited (SPIL) shares are under watch today as the company disclosed a major acquisition deal within the country which adds to its foothold in the pharma and specialty chemicals value chain. The micro cap stock, which has recently turned into a multibagger, has astonishingly given returns of 307% and 502% over the last 1 year and 2 years, respectively. Currently, the stock trades below Rs 50 after a 1:10 stock split conducted four months back.

The stock listed at BSE opened almost 1% up at Rs 32.15 compared to its last closing of Rs 31.99. At 9:45 AM, the counter was trading flat with a slightly positive bias at Rs 31.00. Though there was lackluster movement today, the renowned aggressive growth tactics and recent acquisitions from the company are the main reasons why the attention from investors has not shifted even for a second.

Based on the disclosure with the BSE, SPIL has purchased 2,09,100 equity shares of Ishwari Healthcare, each having a face value of Rs 10, for a revised total consideration of Rs 1.5 Crore. The purchase price for the shares was Rs 71.73 each, which gave SPIL 51% controlling stake in the company. The deal was completed on April 1, 2025, after which Ishwari Healthcare became a Sudarshan Pharma subsidiary.

This is coming right after SPIL declared its international expansion plans. As mentioned earlier, on November 29 2024, the company acquired 10,000 ordinary shares of Sudarshan Pharma Industries Private Limited, Singapore, from Mr. Amar Ashok Vyas for a total consideration of 10,000 Singapore Dollars (INR 6.35 Lakh). With this acquisition, the Sudarshan Group of Companies Singapore became a wholly owned subsidiary which enhances the company's global vision and reach.

SPIL had issued shares to the public for the first time in March 2023 at a price of Rs 73 per share. The last reported stock after SPIL went public was Rs 103. In November 2024, the Company approved a stock split at the ratio of 10 to 1. Changing each Rs 10 face value share to ten Rs 1 shares. This increased liquidity substantially and made the stock more appealing to retail investors, helping maintain interest on the counter.

According to the September 2024 FIH shareholding pattern, promoters continue to hold a majority stake of 57.39% as well as Foreign Institutional Investors (FIIs) holding 13.07%, while the rest 29.54% is owned by non-institutional investors.

Set up in 2008 and located in Mumbai, SPIL is a well-known contract manufacturer of generic pharmaceutical formulations. The company's segments of specialty chemicals, APIs, intermediates and branded pharmaceuticals like Vimac Healthcare division focus on growing markets. Out of the 96 products that SPIL offers, 56 are registered with 'R' trademark. SPIL has established long-term relationships with valued Indian companies and institutions to provide them with comprehensive contract manufacturing services.

Domestic and global acquisitions are coupled with a growing product portfolio, which positions SPIL as one of the most emerging dynamics in the pharmaceutical and specialty chemicals sector.